In the Fall 2024 CIHR funding round, the Department of Medicine (DOM) secured overÌý$14.5 million, accounting forÌý34% of the Faculty's total CIHR fundingÌý²¹²Ô»åÌý29% of 91ÉçÇøâ€™s total CIHR funding. This includes more thanÌý$12 millionÌýawarded to DOM researchers at the RI-MUHC, representingÌý70% of the RI-MUHC’s total CIHR funding, and overÌý$2.4 millionÌýawarded to DOM researchers at the LDI, making upÌý43% of the LDI’s total CIHR funding. These results reflect a slight increase compared to the previous round.
Congratulations to the following 91ÉçÇø Department of Medicine project grant awardees for their successful Fall 2024 CIHR applications!Ìý
Project Grant Awardees (listed in alphabetical order by PI):
Dr. Matthew Cheng -ÌýA Randomized Controlled Trial of Oral Antimicrobial Therapy for Patients with Staphylococcus aureus Bacteremia: The Early Oral Switch Domain in the Staphylococcus aureus Network Adaptive Trial (EOS-SNAP)Ìý
Dr. Inés Colmegna -ÌýInvestigating the anti-fibrotic effects of human multipotent mesenchymal stromal cellsÌý
Dr. Stella S. Daskalopoulou -ÌýClinical Investigation – A: Reproduction, Maternal, Child and Youth Health 2Ìý
Dr. Gustavo Duque -ÌýInvestigating the Diagnostic and Therapeutic Role of the Kynurenine Pathway in OsteosarcopeniaÌý
Dr. Christina Greenaway -ÌýGetting to hepatitis B elimination in Canada: Where are the gaps and how best to fill them?
Dr. Sabah Hussain -ÌýRegulation of skeletal muscle and peroxisomal homeostasis by Depp1 proteinÌý
Dr. Bertrand Jean-Claude -ÌýEngineering metabolically stable molecules toward tandem targeting of EGFR, its variant EGFRvIII and DNA for killing stem cells and preventing recurrence in the treatment of glioblastom multiforme (GBM)Ìý
Dr. Todd C. Lee -ÌýAn international platform for finding the optimal therapies for Pneumocystis jirovecii pneumonia:Ìý The PCP PlatformÌý
Dr. Ivan Litvinov -ÌýCo-creating and implementing integrated dermatology care and augmenting skin research in Quebec northern Indigenous communitiesÌý
Dr. Basil PetrofÌý -ÌýThe role of trained macrophages in dystrophic diaphragm pathologyÌý
Dr. Louise Pilote -ÌýRole of Sex and Gender on Hypertension-mediated Multi-organ DamageÌý
Dr. Stéphane Richard -ÌýEpigenetic modulation to enhance CD8+ T cells for improved antitumour activityÌý
Dr. Abhinav Sharma -ÌýDelivering Evidence-Based Care Using Artificial Intelligence to Patients with Diabetes and CardioVascular Comorbidities: From Proof of Concept to Multi-Centre Expansion (DECIDE-CV-2)Ìý
Dr. Rhian Touyz -ÌýRho kinase as a novel therapeutic target in small vessel disease and vascular dementia – insights from a Notch3 disease
Dr. Oriana Hoi Yun Yu -ÌýThe association between levothyroxine treatment and the risk of metabolic dysfunction-associated steatotic liver disease among people with subclinical hypothyroidism
Priority Announcement Grant AwardeesÌý(listed in alphabetical order by PI):
Dr. Claire Godard-Sebillotte -ÌýAméliorer l’équité en première ligne pour les personnes avec troubles neurocognitifs majeurs: Une étude à méthodes mixtes axée sur le patient
Dr. Thomas Mavrakanas -ÌýEffect of Canagliflozin on Peritoneal Function and Fibrosis in Patients on Peritoneal Dialysis: a proof-of-concept randomized crossover clinical trial (CAN-PD trial)
Dr. Shaifali Sandal -ÌýDisaster risk reduction and management in kidney care to foster health system resilience
Dr. Giada Sebastiani -ÌýELITE-2D: Enhancing Liver Health for People with Type 2 Diabetes through Patient-Centred Strategies
Ìý
The Department extends its sincere appreciation to the Canadian Institutes of Health Research (CIHR) and the Government of Canada for their continued support of medical research. This investment not only drives innovation and enhances patient care but also strengthens Canada’s position as a leader in global health research. We are proud to contribute to this shared mission and remain committed to advancing scientific discovery for the benefit of our communities.
Related:Ìý
Ìý(CIHR website)Ìý